Archive | May, 2012

New page listing ongoing analyses with PPMI data

A new page has been added to the site to highlight all of the proposed analyses submitted by individuals who sign up to access the data. Individuals who are interested in using PPMI data can use this resource to better understand potential uses of the data, identify collaborators, and spark new research ideas.

Continue reading...

MDS Presentation on PPMI- Associations between brain microstructural and dopaminergic integrity in PD: A joint diffusion tensior and DAT imaging study

Reduced 123I-DAT measures of the putamen as well as of the caudate were associated most prominently with reduced FA values near the right supplementary motor areas (SMA) and medial part of the motor cortex (p < 0.001, at a cluster level of 100 voxels). In contrast, increasing symptom severity was associated primarily with reduced FA values bilaterally in the substantia nigra as well as in some regions in the brain stem (p < 0.001, at a cluster level of 100 voxels)

Continue reading...

MDS Presentation on PPMI- Association between CSF biomarkers and clinical phenotype of early Parkinson’s disease

We found that the level of tau proteins (t-tau and p-tau181) and a-syn in CSF of these untreated PD patients were significantly lower than those of HC, and that CSF a-syn concentration was significantly correlated with the concentrations of CSF tau proteins. Further investigations are planned to test the predictive performance of the biomarkers for disease progression.

Continue reading...

MDS Presentation on PPMI- Baseline neuroimaging characteristics

Quantitative DAT SPECT imaging data acquired at baseline in PD and healthy volunteers demonstrate expected cohort differences in this multicenter trial with values consistent with previously reported single center 123-I Ioflupane SPECT studies. Longitudinal data are pending.

Continue reading...

MDS Presentation on PPMI- Frequency of Impulse Control Disorders in PD vs. Controls

These results suggest that PD itself does not confer an increased risk for development of ICD symptoms and related behaviors, which reinforces the reported association between PD medications and ICDs in PD. Given that approximately 20% of untreated PD patients screen positive for ICD or related symptoms, long-term follow-up of the PPMI cohort will determine if such patients are at increased risk of ICD development when PD medications are initiated.

Continue reading...

MDS Presentation on PPMI- Diurnal and intersubject variability of cerebrospinal fluid biomarkers in Parkinson’s disease and healthy volunteers

Increases in biomarkers such as alpha-synuclein and Abeta species over 26 hours may reflect a gradient effect by frequent CSF sampling at multiple time points over one day. Additionally, it will be important to account for total protein and hemoglobin levels when measuring certain CSF biomarkers. This will be critical to the design of future clinical trials utilizing CSF biomarkers as endpoints.

Continue reading...

Moderated stats forum addresses questions on PPMI data

A statistics forum has been created to help investigators who are interested in accessing or who have accessed the PPMI database find additional information about the dataset.

Continue reading...

Keeping participants engaged over time: PPMI retention events

Retention is quickly becoming a key priority as over half of the PD cohort in PPMI is recruited. PPMI retention events are proving to be an important strategy to bring PPMI participants together, share study updates and answer questions.

Continue reading...

All These People, Working for Us

PPMI Patient Committee member, Peter Burne, reflects on his experience attending the PPMI Annual Meeting in early May in New York City.

Continue reading...

Upcoming presentations on PPMI at The Movement Disorders Society International Congress

Five abstracts will be presented at MDS in mid-June. Learn more about the topics that will be covered.

Continue reading...